Annual Report

Overview

The report describes InnoCare's top-down ESG governance, with the Board overseeing ESG decisions and an ESG Working Group coordinating implementation. It highlights a 13-drug clinical-stage pipeline, more than 30 global clinical trials, and continued commercialization of Orelabrutinib and Tafasitamab. For 2022, the report discloses 9,835.80 tons of CO2 equivalent of GHG emissions and 981 employees, alongside expanded product-accessibility and R&D activities.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Publication date: 27 March 2023
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services